← All trials
NCT05118386
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Jul 1, 2022
- Completion date
- Aug 5, 2022
- First posted
- Nov 12, 2021
- Last posted
- Nov 12, 2021
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bill and Melinda Gates FoundationLead sponsor
- Bill and Melinda Gates FoundationStudy director
- PPDCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.